Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03352596
Other study ID # 93567
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 13, 2017
Last updated November 20, 2017
Start date January 1, 2017
Est. completion date November 30, 2017

Study information

Verified date August 2017
Source National Nutrition and Food Technology Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetes is one of the most common and chronic diseases in the world, with the prevalence and incidence of this disease rising in most societies, especially in Iran. Suitable treatments for type 2 diabetes include changing lifestyle with exercise, nutrition, and drug use. New research suggests that added sugar, especially fructose, is the main trigger for diabetes and pre-diabetes even more potent than other carbohydrates. Fructose has a low glycemic index (23μg =) and slowly increases blood glucose levels. Therefore, it is thought that replacing fructose instead of glucose can have a positive effect on glycemic control of diabetic patients..


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 48
Est. completion date November 30, 2017
Est. primary completion date October 1, 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

1. Age of 70-40 years

2. body mass index(BMI) between 18.5 and 27

3. Type 2 diabetes People who only control their diabetes by using glucose lowering tablets Type 2 diabetes (1 to 10 years)

Exclusion Criteria:

1. Pregnancy and lactation

2. Thyroid gland disorders

3. Kidney disease and inflammation

4. Follow the weight loss regimen 6 months before starting the study

5. Usage of fatty and fatty foods, fiber powder Vitamin A Mineral Supplements, Omega 3

6. Taking glucocorticoid drugs and non-steroidal anti-inflammatory drugs

Study Design


Intervention

Other:
low frutose diet


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Nutrition and Food Technology Institute

Outcome

Type Measure Description Time frame Safety issue
Primary fasting blood suger(FBS) 8 weeks
Primary Homeostatic model assessment and insulin resistance(HOMA-IR) 8weeks
Primary insulin 8 weeks
Secondary Triglyceride 8 weeks
Secondary Total cholestrole 8 weeks
Secondary LDL-C 8 weeks
Secondary HDL-C 8 weeks
Secondary Blood pressure 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03939130 - Fructose Rich Diet and Endothelial Function N/A
Active, not recruiting NCT05826717 - Effect of Matrices on Serum Fructose. N/A